Hormonal
Obesity is a chronic disease driven by hypothalamic dysregulation of body fat mass set points, not by individual neglect of eating habits or exercise.
Stop blaming yourself for your weight. Your body is biologically defending a higher fat mass set point due to hypothalamic dysregulation. This is a chronic disease, not a moral failing. Effective treatment requires addressing this biology (e.g., via medications or surgery that target these pathways) rather than relying solely on willpower or calorie counting, which often fail because they trigger metabolic adaptation.
Such presumed personal choices do not constitute a disease, they are modifiable risk factors. On the other hand, if these external contributors, such as the environment of psychological state, are instead influencing expression of an innate biology, then the final common pathway to obesity is, instead, internal to the body and reflects disrupted physiology.
Why this rating
Review of decades of basic and outcomes research, including animal models and human clinical observations.
Source
Hypothalamic control of body fat mass by food intake: The key to understanding why obesity should be treated as a disease
Jonathan Q. Purnell et al. · Diabetes Obesity and Metabolism · 2024
DOI 10.1111/dom.15478
More from this paper
- The hypothalamus regulates body fat mass through a defended set point, where afferent signals from gut hormones (GLP-1, CCK, ghrelin) and adipose tissue (leptin) modulate food intake and energy expenditure.Strong
- Anti-obesity medications (GLP-1 RAs, MC4R agonists) and bariatric surgery work by improving appetite control and resetting the fat mass set point, rather than just creating a caloric deficit.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →